Zynerba Pharmaceuticals Inc. (ZYNE)

12.55
0.44 3.39
NASDAQ : Health Technology
Prev Close 12.99
Open 12.98
Day Low/High 12.36 / 13.08
52 Wk Low/High 2.75 / 16.47
Volume 1.04M
Avg Volume 2.67M
Exchange NASDAQ
Shares Outstanding 21.07M
Market Cap 281.07M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
First Week Of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)

First Week Of July 19th Options Trading For Zynerba Pharmaceuticals (ZYNE)

Investors in Zynerba Pharmaceuticals Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

Uncertainty over the trade war's effects on earnings make this market really hard on investors, says Jim Cramer.

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Jim Cramer takes a look at Lululemon Athletica, Wayfair, Amazon, Intrexon, Iridium Communications, PayPal, Zscaler, Zynerba Pharmaceuticalsm and more.

Interesting ZYNE Put And Call Options For June 21st

Interesting ZYNE Put And Call Options For June 21st

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

There Is Generally Good Action on My Screens Today

There Is Generally Good Action on My Screens Today

The price action is quite good.

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

I Have My Eye on This Warren Buffett Stock Amid the Choppy Action

Market players are more skeptical of the quick moves on U.S.-China trade news.

5 Stocks on My Radar During a Quiet Day

5 Stocks on My Radar During a Quiet Day

Sometimes dull action like this can be good for trading.

SCYNEXIS Reports Full Year 2018 Financial Results And Provides Company Update

SCYNEXIS Reports Full Year 2018 Financial Results And Provides Company Update

Phase 3 VANISH program underway, evaluating oral ibrexafungerp for the treatment of acute VVC; anticipate top-line data in the first half of 2020 with NDA submission in the second half of 2020

Is Apple Aggressively Buying Back Its Stock?

Is Apple Aggressively Buying Back Its Stock?

Without Apple doing so well Monday the indices would look much different.

The Action in Select Small Caps Is Encouraging

The Action in Select Small Caps Is Encouraging

It's tough to do much while we await major news events.

SCYNEXIS Announces Appointment Of Industry Veteran Armando Anido To Its Board Of Directors

SCYNEXIS Announces Appointment Of Industry Veteran Armando Anido To Its Board Of Directors

Brings executive, operational, business development and commercial leadership expertise based on over 30 years in the biopharmaceutical industry

First Week Of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)

First Week Of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Insiders Find Value In These 3 Small Caps

Insiders Find Value In These 3 Small Caps

This sort of insider activity often coincides with a turnaround in these types of beaten down equities.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

Interesting ZYNE Put And Call Options For November 16th

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

My Buy-Write Strategy Amid Market Swings

My Buy-Write Strategy Amid Market Swings

It's a simple option strategy to mitigate some risk in deploying new funds.

Zynerba Pharmaceuticals Reaches Analyst Target Price

Zynerba Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Zynerba Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $13.00, changing hands for $13.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: D- (Sell)